Page last updated: 2024-10-29

ketamine and Anankastic Personality

ketamine has been researched along with Anankastic Personality in 19 studies

Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.

Research Excerpts

ExcerptRelevanceReference
"The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder."9.24Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017)
"We previously reported the rapid and robust clinical effects of ketamine versus saline infusions in a proof-of-concept crossover trial in unmedicated adults with obsessive-compulsive disorder (OCD)."9.20In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. ( Flood, P; Hunter, L; Kegeles, LS; Levinson, A; Mao, X; Milak, MS; Moore, H; Ogden, RT; Rodriguez, CI; Shungu, DC; Simpson, HB; Vermes, D; Xie, S, 2015)
"Ketamine has shown some promise in treating OCD."5.56Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. ( Arumugham, SS; Balachander, S; Jaisoorya, TS; Janardhanan, CN; Reddy, YCJ; Sharma, LP; Thamby, A, 2020)
"Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with low risk of severe respiratory depression."5.39Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. ( Bloch, MH; Corlett, PR; Grunschel, BD; Niciu, MJ; Pittenger, C, 2013)
"Ketamine is a potent noncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor."5.38Effects of ketamine in treatment-refractory obsessive-compulsive disorder. ( Bhagwagar, Z; Billingslea, E; Bloch, MH; Krystal, JH; Landeros-Weisenberger, A; Leckman, JF; Panza, KE; Pittenger, C; Sanacora, G; Wasylink, S, 2012)
"The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder."5.24Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017)
"We previously reported the rapid and robust clinical effects of ketamine versus saline infusions in a proof-of-concept crossover trial in unmedicated adults with obsessive-compulsive disorder (OCD)."5.20In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. ( Flood, P; Hunter, L; Kegeles, LS; Levinson, A; Mao, X; Milak, MS; Moore, H; Ogden, RT; Rodriguez, CI; Shungu, DC; Simpson, HB; Vermes, D; Xie, S, 2015)
"Ketamine has shown some promise in treating OCD."1.56Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. ( Arumugham, SS; Balachander, S; Jaisoorya, TS; Janardhanan, CN; Reddy, YCJ; Sharma, LP; Thamby, A, 2020)
"Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with low risk of severe respiratory depression."1.39Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. ( Bloch, MH; Corlett, PR; Grunschel, BD; Niciu, MJ; Pittenger, C, 2013)
"Ketamine is a potent noncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor."1.38Effects of ketamine in treatment-refractory obsessive-compulsive disorder. ( Bhagwagar, Z; Billingslea, E; Bloch, MH; Krystal, JH; Landeros-Weisenberger, A; Leckman, JF; Panza, KE; Pittenger, C; Sanacora, G; Wasylink, S, 2012)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (68.42)24.3611
2020's6 (31.58)2.80

Authors

AuthorsStudies
Davis, GL1
Minerva, AR1
Lario, A1
Simmler, LD1
Rodriguez, CI7
Gunaydin, LA1
Bottemanne, H1
Arnould, A1
Najar, A1
Delaigue, F1
Serresse, L1
Joly, L1
Mouchabac, S1
Thompson, SL1
Welch, AC1
Iourinets, J1
Dulawa, SC1
Peyrovian, B1
McIntyre, RS1
Phan, L1
Lui, LMW1
Gill, H1
Majeed, A1
Chen-Li, D1
Nasri, F1
Rosenblat, JD1
Sharma, LP1
Thamby, A1
Balachander, S1
Janardhanan, CN1
Jaisoorya, TS1
Arumugham, SS1
Reddy, YCJ1
Veraart, JKE1
Kamphuis, J1
Schlegel, M1
Schoevers, RA1
Glue, P1
Medlicott, NJ1
Harland, S1
Neehoff, S1
Anderson-Fahey, B1
Le Nedelec, M1
Gray, A1
McNaughton, N1
Lapidus, KAB1
Zwerling, J3
Levinson, A4
Mahnke, A1
Steinman, SA2
Kalanthroff, E1
Simpson, HB6
M Koran, L1
Aboujaoude, E1
Tosta, CL1
Silote, GP1
Fracalossi, MP1
Sartim, AG1
Andreatini, R1
Joca, SRL1
Beijamini, V1
Niciu, MJ1
Grunschel, BD1
Corlett, PR1
Pittenger, C3
Bloch, MH3
Kegeles, LS3
Feng, T1
Marcus, SM1
Vermes, D3
Flood, P3
Wink, LK1
O'Melia, AM1
Shaffer, RC1
Pedapati, E1
Friedmann, K1
Schaefer, T1
Erickson, CA1
Ogden, RT1
Mao, X1
Milak, MS1
Xie, S1
Hunter, L1
Moore, H1
Shungu, DC1
Wheaton, M1
Sonnenfeld, D1
Galfalvy, H1
Adams, TG1
Wasylink, S1
Landeros-Weisenberger, A1
Panza, KE1
Billingslea, E1
Leckman, JF1
Krystal, JH1
Bhagwagar, Z1
Sanacora, G1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Ketamine Infusion for Social Anxiety Disorder[NCT02083926]Early Phase 118 participants (Actual)Interventional2015-01-02Completed
Ketamine Infusion for Obsessive-Compulsive Disorder[NCT01349231]Phase 210 participants (Actual)Interventional2009-02-28Completed
Understanding the Glutamate System in Adults With Obsessive-Compulsive Disorder With N-methyl-D Aspartate Antagonist Ketamine[NCT01100255]Phase 215 participants (Actual)Interventional2010-04-30Completed
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290]Phase 1/Phase 25 participants (Actual)Interventional2015-03-31Completed
Extending Ketamine's Effects in Obsessive-Compulsive Disorder (OCD) With Exposure and Response Prevention (EX/RP)[NCT02062658]Phase 210 participants (Actual)Interventional2013-12-31Completed
Open -Label Trial on the Effects of Memantine in Adults With Obsessive-Compulsive Disorder After a Single Ketamine Infusion[NCT00956085]Phase 212 participants (Actual)Interventional2009-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Liebowitz Social Anxiety Score (LSAS)

Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)

Interventionscore on a scale (Mean)
Ketamine Infusion on Day 0 or Day 2866.1
Saline Infusion on Day 0 or Day 2886.1

Visual Analogue Scale for Anxiety Symptoms (VAS-anxiety)

"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)

Interventionunits on a scale (Mean)
Ketamine Infusion on Day 0 or Day 2812.1
Saline Infusion on Day 0 or Day 2819.6

OCD Severity

We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 1 day following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 1 day after ketamine infusion

Interventionunits on a scale (Mean)
Ketamine-2.7

OCD Severity

We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 2 days following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 2 days following infusion

Interventionunits on a scale (Mean)
Ketamine-3.6

OCD Severity

We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 3 days following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 3 days following infusion

Interventionunits on a scale (Mean)
Ketamine-2.9

Depression Symptoms

We will examine change from baseline in Hamilton Rating Scale for Depression (HRDS) ratings of depression severity at day 1-3 following a single ketamine infusion. The HRDS assesses severity of, and change in, depressive symptoms. The HRDS is a 21 item scale with scores ranging from 0-66. The higher the score, the more severe the depression. (NCT01349231)
Timeframe: Baseline, Day 1, Day 2, and Day 3

Interventionunits on a scale (Mean)
HRDS change from Baseline to Day 1HRDS change from Baseline to Day 2HRDS change from Baseline to Day 3
Ketamine-6.57-7.29-5.14

Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.

Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS. (NCT01100255)
Timeframe: 1 week

Interventionparticipants (Number)
Saline Infusion0
Ketamine Infusion5

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported

Interventionscore on a scale (Mean)
CY-BOCS BaselineCY-BOCS Day 14
Ketamine Treatment Group29.0026.20

Clinical Global Impressions - Severity Scale (CGI-S)

The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported

Interventionscore on a scale (Mean)
CGI-S BaselineCGI-S Day 14
Ketamine Treatment Group5.805.00

OCD Visual Analogue Scale (OCD-VAS)

"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported

Interventionscore on a scale (Mean)
OCD-VAS BaselineOCD-VAS Day 14
Ketamine Treatment Group5.005.00

Yale-Brown Obsessive Compulsive Challenge Scale (Y-BOCCS)

"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported

Interventionscore on a scale (Mean)
Y-BOCCS BaselineY-BOCCS Day 14
Ketamine Treatment Group18.2516.50

Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale

Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS. (NCT02062658)
Timeframe: 2 weeks

Interventionparticipants (Number)
Ketamine, Exposure & Response Prevention5

Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.

Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS. (NCT00956085)
Timeframe: Baseline and 6 weeks

InterventionParticipants (Count of Participants)
Memantine4

Reviews

1 review available for ketamine and Anankastic Personality

ArticleYear
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research.
    Current medicinal chemistry, 2018, Volume: 25, Issue:41

    Topics: Caffeine; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Ketamine; Memantine; Obse

2018

Trials

6 trials available for ketamine and Anankastic Personality

ArticleYear
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
    Journal of psychopharmacology (Oxford, England), 2017, Volume: 31, Issue:10

    Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Depression; Depressiv

2017
Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder.
    The Journal of clinical psychiatry, 2017, Volume: 78, Issue:4

    Topics: Administration, Intranasal; Adolescent; Adult; Drug Administration Schedule; Excitatory Amino Acid A

2017
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:12

    Topics: Adult; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; K

2013
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:12

    Topics: Adult; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; K

2013
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:12

    Topics: Adult; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; K

2013
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:12

    Topics: Adult; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; K

2013
In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.
    Psychiatry research, 2015, Aug-30, Volume: 233, Issue:2

    Topics: Adult; Cross-Over Studies; Excitatory Amino Acid Antagonists; Female; gamma-Aminobutyric Acid; Gluta

2015
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.
    The Journal of clinical psychiatry, 2016, Volume: 77, Issue:3

    Topics: Administration, Intravenous; Adolescent; Adult; Cognitive Behavioral Therapy; Combined Modality Ther

2016
Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.
    The Journal of clinical psychiatry, 2016, Volume: 77, Issue:5

    Topics: Administration, Intravenous; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Subs

2016

Other Studies

12 other studies available for ketamine and Anankastic Personality

ArticleYear
Ketamine increases activity of a fronto-striatal projection that regulates compulsive behavior in SAPAP3 knockout mice.
    Nature communications, 2021, 10-15, Volume: 12, Issue:1

    Topics: Animals; Compulsive Behavior; Corpus Striatum; Disease Models, Animal; Female; Grooming; Humans; Ket

2021
[Combination of ketamine and esketamine with Exposure and Response Prevention (ERP) therapy for Obsessive-Compulsive Disorder].
    L'Encephale, 2023, Volume: 49, Issue:3

    Topics: Extinction, Psychological; Fear; Humans; Implosive Therapy; Ketamine; Obsessive-Compulsive Disorder;

2023
Ketamine induces immediate and delayed alterations of OCD-like behavior.
    Psychopharmacology, 2020, Volume: 237, Issue:3

    Topics: Animals; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Female; Ketamine; Mice

2020
Registered clinical trials investigating ketamine for psychiatric disorders.
    Journal of psychiatric research, 2020, Volume: 127

    Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Obsessive-Compulsive Disorder;

2020
Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder.
    Asian journal of psychiatry, 2020, Volume: 52

    Topics: Adult; Humans; Infusions, Intravenous; Ketamine; Obsessive-Compulsive Disorder; Selective Serotonin

2020
Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities.
    BMJ case reports, 2021, Jan-25, Volume: 14, Issue:1

    Topics: Administration, Oral; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Clozapine; D

2021
S-ketamine reduces marble burying behaviour: Involvement of ventromedial orbitofrontal cortex and AMPA receptors.
    Neuropharmacology, 2019, Volume: 144

    Topics: Animals; Drug Evaluation, Preclinical; Ketamine; Male; Mice; Motor Activity; Obsessive-Compulsive Di

2019
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:7

    Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Humans; Ketamine; Middle Aged; Obsessive-Compuls

2013
Intranasal ketamine treatment in an adult with autism spectrum disorder.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:8

    Topics: Administration, Intranasal; Adult; Anorexia Nervosa; Child Development Disorders, Pervasive; Depress

2014
Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:2

    Topics: Administration, Intranasal; Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Mod

2017
Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4

    Topics: Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Intravenous; Keta

2011
Effects of ketamine in treatment-refractory obsessive-compulsive disorder.
    Biological psychiatry, 2012, Dec-01, Volume: 72, Issue:11

    Topics: Adolescent; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2012